Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Appropriators Continue Pressing US FDA To Conduct Surprise In-Person Inspections

Executive Summary

The bill also would give the FDA expanded authority over nicotine products and create President Biden’s Advanced Research Projects Agency for Health.

You may also be interested in...



Drugs From Sponsors ‘Located in Russia,’ Would Be Barred From US FDA Review By House Funding Bill

Language of the amendment cleared by appropriators in response to the Russian war against Ukraine in FDA’s fiscal year funding bill is vague, making impact of the funding ban on industry unclear. Democrats supported the amendment but said they wanted to continue to work on language to avoid “unintended consequences.” FDA would get a 10% bump in non-user fee funds under the bill.

US FDA’s Califf Notes ‘Price To Pay’ For Missed Inspections During Senate COVID Funding Hearing

As Senate HELP Committee meetings questioned Commissioner Califf about backlog of inspections and FDA staff continuing to work remotely, Sen. Burr promises to be a roadblock to emergency COVID-19 funding.

US FDA’s Califf Acknowledges There Is ‘Price To Pay’ For Missed Inspections

Commissioner Califf is questioned about the backlog of inspections and fact FDA staff are continuing to work remotely at Senate HELP Committee hearing. Senator Burr promises to be a roadblock to emergency COVID-19 funding.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel